Vaccinex, Inc. (VCNX)
NASDAQ: VCNX · Real-Time Price · USD
3.710
+0.400 (12.08%)
At close: Nov 20, 2024, 4:00 PM
3.720
+0.010 (0.27%)
After-hours: Nov 20, 2024, 7:24 PM EST
Vaccinex Revenue
Vaccinex had revenue of $52.00K in the quarter ending September 30, 2024, with 160.00% growth. This brings the company's revenue in the last twelve months to $388.00K, down -51.19% year-over-year. In the year 2023, Vaccinex had annual revenue of $570.00K with 107.27% growth.
Revenue (ttm)
$388.00K
Revenue Growth
-51.19%
P/S Ratio
14.77
Revenue / Employee
$9,700
Employees
40
Market Cap
10.37M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Oncology Institute | 378.93M |
ImmunoPrecise Antibodies | 17.44M |
Kiora Pharmaceuticals | 16.02M |
Dominari Holdings | 12.59M |
MSP Recovery | 10.73M |
PAVmed | 4.03M |
Alterity Therapeutics | 2.68M |
VCNX News
- 2 days ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 13 days ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 15 days ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 20 days ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 2 months ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership - GlobeNewsWire
- 4 months ago - Vaccinex stock tanks 40% despite positive Alzheimer's study update - Invezz
- 5 months ago - Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease - GlobeNewsWire